Home » FDA Issues Enforcement Action Based on Non-FDA Inspection
FDA Issues Enforcement Action Based on Non-FDA Inspection
International cooperation between regulators is “taking off” — a trend that could limit the amount of duplicate inspections drugmakers face, a top CDER official says. While “mutual recognition” of inspections is not yet a reality, drugmakers shouldn’t expect the FDA to close its eyes to negative inspection findings from other regulators.
Drug GMP Report
Drug GMP Report
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May